The archive · Bio & Materials · Strategic decision · 2015–2026
Automata bets pharma will run wet labs on one AI-ready automation platform
London-founded Automata sold a desktop robot arm, pivoted to whole-lab automation, and raised a $45M Series C led by Dimension with Danaher.
Automata
What the business is
Automata, founded in London in 2015, builds lab automation for life sciences. Its platform combines LINQ, cloud-based orchestration software that integrates instruments and lets users design, schedule and run multistep workflows, with modular robotic benches that physically move labware across a lab; the company says the platform is the reference architecture for autonomous wet labs, making experiments programmable, repeatable and AI-ready. Instruments from Danaher's Beckman Coulter Life Sciences and Molecular Devices now integrate with LINQ.
Starting capital：$45M Series C announced January 29, 2026, led by Dimension with Danaher Ventures, Tru Arrow Partners, Octopus Ventures and Entrepreneurs First. Danaher Corporation made a strategic investment alongside, with Murali Venkatesan of Danaher Ventures joining the board. Automata previously raised a $40M round led by Dimension in October 2023.
How it started
Automata was founded in London in 2015 and initially sold Eva, a configurable desktop robot arm for automating repetitive manual tasks in any industry. TechCrunch's October 2023 profile reports that the company concluded serving smaller, individualized use cases would not scale into a meaningful business, so it pivoted to sectors on the brink of an automation revolution, focusing on genomics and cell biology labs. The new 'Automata 2.0' stack couples LINQ, a cloud platform for designing and running workflows, with the modular LINQ robotic bench that moves labware between instruments.
What happened
Automata's pivot attracted a customer roster including AstraZeneca, UK NHS trusts and the Francis Crick Institute by October 2023, when it raised a $40M round led by Dimension. On January 29, 2026 the company announced a $45M Series C — again led by Dimension, joined by Danaher Ventures, Tru Arrow Partners, Octopus Ventures and Entrepreneurs First — alongside a strategic partnership with Danaher under which Beckman Coulter Life Sciences and Molecular Devices instruments integrate into LINQ, with Danaher Ventures' Murali Venkatesan joining the board.
How it ended up
As of late January 2026 Automata was scaling: it says five top pharma companies are customers, with repeat deployments on some of the industry's largest automation projects, and the new capital will fund larger deployments, global engineering and customer-success growth, and the next version of its closed-loop experimentation software for AI-driven drug discovery. Revenue and profitability are undisclosed.
Background
Automata was founded in London in 2015 and first sold Eva, a configurable desktop robot arm meant to automate repetitive manual tasks in any industry. By its own account, small, individualized use cases were not going to scale into a meaningful business, so the company went back to the drawing board and rebuilt around full lab automation for genomics and cell biology, a pivot TechCrunch covered in October 2023.
The rebuilt product is LINQ: cloud software that integrates instruments and lets scientists design, schedule and run multistep workflows, plus a modular robotic bench that physically moves labware. Automata calls this the reference architecture for autonomous wet labs — modular robotics, orchestration software and unified data that turn physical labs into programmable, repeatable, AI-ready systems, where scientists program experiments rather than robots.
On January 29, 2026 Automata announced a $45M Series C led by Dimension, with Danaher Ventures, Tru Arrow Partners, Octopus Ventures and Entrepreneurs First participating. Danaher Corporation also made a strategic investment: instruments from its Beckman Coulter Life Sciences and Molecular Devices businesses will integrate into LINQ, and Murali Venkatesan, Danaher Ventures' global head, joined Automata's board. The company had raised a $40M round led by Dimension in October 2023.
Automata says five top pharma companies are customers, with repeat deployments on some of the industry's largest automation projects, and that the platform improves experimental throughput, reproducibility and resource efficiency. The capital is earmarked for scaling deployments, expanding global operations and building the next version of its closed-loop experimentation software. No revenue or profitability figures have been disclosed, so the open question is whether a platform business can capture a fragmented market of labs and instruments at the pace the AI wave promises.
What has to be true
- Full-lab automation outflanks a single robot arm: LINQ orchestrates instruments the lab already owns, so the workflow — not one task — is the product.
- Danaher is a distribution shortcut: Beckman Coulter Life Sciences and Molecular Devices instruments now integrate into LINQ, handing Automata an installed base it never had to sell.
- The pivot came from evidence, not panic: Automata's own experience selling small, individualized use cases showed the business would not scale before it rebuilt for genomics and cell biology labs.
- AI made physical labs the bottleneck: with computational biology racing ahead, 'programmable, repeatable, AI-ready' wet labs became an infrastructure category pharma budgets would fund.
What can be applied
Partial automation competes on price per task; Automata won by making the whole lab the product, so every instrument a customer already owns is a reason to buy the platform.
Aftermath
As of January 29, 2026, Automata was spending a $45M Series C to scale customer deployments, grow engineering and customer-success teams globally, and build the next iteration of its closed-loop experimentation software. The Danaher partnership puts Beckman Coulter Life Sciences and Molecular Devices instruments inside LINQ and seats Danaher Ventures on the board. Automata says five top pharma companies are customers with repeat deployments, but no revenue is disclosed, and whether one platform can capture a fragmented wet-lab market was still being tested.
Sources
- Science lab automation and robotics startup Automata raises $40M
- Automata Secures $45M Series C to Scale AI-Ready Lab Automation
- Automata Raises $45M Series C to Power AI-Driven, Autonomous Life Science Labs
- Beckman Coulter Life Sciences partners with Automata
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card